

Get to know VOXZOGO

The first and only **FDA-approved treatment** to increase linear growth for children of all ages with achondroplasia and open growth plates.

Shawn, 8 years old, receiving VOXZOGO as part of a clinical trial

IMPORTANT SAFETY INFORMATION

What is the most important safety information about VOXZOGO?

- VOXZOGO may cause serious side effects including a temporary decrease in blood pressure in some patients. To reduce the risk of a decrease in blood pressure and associated symptoms (dizziness, feeling tired, or nausea), patients should eat a meal and drink 8 to 10 ounces of fluid within 1 hour before receiving VOXZOGO.

Please see **Important Safety Information** throughout, as well as the full Prescribing Information and Patient Information.

VOXZOGO®
(vosoritide) for injection

With VOXZOGO® (vosoritide), you're part of a community



Over 2,600 children with achondroplasia around the world are being prescribed VOXZOGO*

*Data on file. BioMarin Pharmaceutical Inc.; 2024.



97% of insured patients[†] have secured coverage for VOXZOGO

BioMarin RareConnections™ can help you navigate the insurance process and identify assistance options you may be eligible for to start and continue on treatment.

[†]BioMarin RareConnections Data on File. VOXZOGO patients included are eligible VOXZOGO patients who have enrolled in BioMarin RareConnections and are on commercial therapy. BioMarin RareConnections data from April through December 2023.



One-to-one product education and injection training tailored to your family's needs during your child's entire duration of treatment from a trained BioMarin Clinical Coordinator

What is VOXZOGO used for?

- VOXZOGO is a prescription medicine used to increase linear growth in children with achondroplasia and open growth plates (epiphyses).
- VOXZOGO is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.

Please see Important Safety Information throughout, as well as the full [Prescribing Information](#) and [Patient Information](#).



Shawn, 8 years old,
receiving VOXZOGO as
part of a clinical trial


VOXZOGO®
(vosoritide) for injection

Eve, 3 years old,
receiving VOXZOGO as
part of a clinical trial

It's time to talk about VOXZOGO while your child is still growing

**VOXZOGO® (vosoritide) is approved by the FDA
to increase linear growth for children of all ages
with achondroplasia and open growth plates.**

The period of bone growth is limited



VOXZOGO can help increase linear growth only while your child's growth plates remain open. **Talk to your doctor about starting VOXZOGO early and staying on as long as possible.**

What are the most common side effects of VOXZOGO?

- The most common side effects of VOXZOGO include injection site reactions (including redness, itching, swelling, bruising, rash, hives, and injection site pain), high levels of blood alkaline phosphatase shown in blood tests, vomiting, joint pain, decreased blood pressure, and stomach ache. These are not all the possible side effects of VOXZOGO. Ask your healthcare provider for medical advice about side effects, and about any side effects that bother the patient or that do not go away.

VOXZOGO®
(vosoritide) for injection

Please see **Important Safety Information** throughout, as well as
the full **Prescribing Information** and **Patient Information**.

Children with achondroplasia can grow faster with VOXZOGO than without treatment

1
year

Annualized growth velocity (AGV) in children taking VOXZOGO (n=60) increased from 1.68 inches/year to 2.23 inches/year, while AGV in children taking placebo (n=61) decreased from 1.60 inches/year to 1.53 inches/year

- ▶ In a clinical study of 121 children aged 5 to 15 years, linear growth was measured using AGV over 1 year
- ▶ AGV is linear growth over a 1-year period, and is a measurable way to study the impact of VOXZOGO

97%

3
years

of children (58/60) continued to take VOXZOGO after 1 year*

*One child discontinued due to injection pain, and one child discontinued due to fear of needles.

Improvement in linear growth over baseline (from when treatment was started) was maintained over 3 years in an ongoing study[†]

- ▶ At year 3, AGV was 2.02 inches/year

[†]These results are from an open-label extension study. This study did not have a placebo group, and caregivers, patients, and physicians were aware that all children were given VOXZOGO.

The safety of VOXZOGO was established in 2 robust clinical studies

For patients aged 5 to 15 years, the most common side effects seen in over 10% of VOXZOGO patients over 1 year in a clinical trial were: injection site reddening, injection site swelling, vomiting, injection site hives, joint pain, decreased blood pressure, and stomach ache.

The most common adverse reactions seen in over 10% of VOXZOGO patients under 5 years of age were injection site reactions and rash.

It's important to know:

- ▶ VOXZOGO may cause serious side effects, including a temporary decrease in blood pressure in some patients
- ▶ You can reduce the risk of decreased blood pressure and associated symptoms (dizziness, feeling tired, or nausea) by following these steps in the hour prior to receiving VOXZOGO:
 - ▶ Be well fed
 - ▶ Be well hydrated

The overall safety profile of VOXZOGO in children under the age of 5 was similar to that seen in children aged 5 and up.

Please see Important Safety Information throughout, as well as the full Prescribing Information and Patient Information.

Eve, 3 years old,
receiving VOXZOGO as
part of a clinical trial



VOXZOGO is a daily injection that's given just under your child's skin

- ▶ VOXZOGO uses a short, thin needle—smaller than the one used for most vaccinations
- ▶ Your child's doctor will train you on how to give VOXZOGO
- ▶ BioMarin Clinical Coordinators can reinforce injection training provided by your child's doctor—whenever you need it, throughout your child's time on treatment

Simple growth and weight checkups are important for children taking VOXZOGO.
Work with your child's doctor to:



Get regular measurements taken
every 3 to 6 months



Get regular growth-specific monitoring from
a specialist, like a pediatric endocrinologist

It's important to remember that every child is unique. Even with VOXZOGO, each child will grow at different times and at different speeds.

Find care for your child



Locate a healthcare provider in your area

Scan the QR code to visit the Achondroplasia Doctor Finder and locate healthcare providers in your area who have expressed an interest in caring for children with achondroplasia.

Please see **Important Safety Information** throughout, as well as the full **Prescribing Information** and **Patient Information**.

IMPORTANT SAFETY INFORMATION

What is VOXZOGO® (vosoritide) used for?

- VOXZOGO is a prescription medicine used to increase linear growth in children with achondroplasia and open growth plates (epiphyses).
- VOXZOGO is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.

What is the most important safety information about VOXZOGO?

- VOXZOGO may cause serious side effects including a temporary decrease in blood pressure in some patients. To reduce the risk of a decrease in blood pressure and associated symptoms (dizziness, feeling tired, or nausea), patients should eat a meal and drink 8 to 10 ounces of fluid within 1 hour before receiving VOXZOGO.

What are the most common side effects of VOXZOGO?

- The most common side effects of VOXZOGO include injection site reactions (including redness, itching, swelling, bruising, rash, hives, and injection site pain), high levels of blood alkaline phosphatase shown in blood tests, vomiting, joint pain, decreased blood pressure, and stomach ache. These are not all the possible side effects of VOXZOGO. Ask your healthcare provider for medical advice about side effects, and about any side effects that bother the patient or that do not go away.

How is VOXZOGO taken?

- VOXZOGO is taken daily as an injection given under the skin, administered by a caregiver after a healthcare provider determines the caregiver is able to administer VOXZOGO. Do not try to inject VOXZOGO until you have been shown the right way by your healthcare provider. VOXZOGO is supplied with Instructions for Use that describe the steps for preparing, injecting, and disposing VOXZOGO. Caregivers should review the Instructions for Use for guidance and any time they receive a refill of VOXZOGO in case any changes have been made.
- Inject VOXZOGO 1 time every day, at about the same time each day. If a dose of VOXZOGO is missed, it can be given within 12 hours from the missed dose. After 12 hours, skip the missed dose and administer the next daily dose as usual.
- The dose of VOXZOGO is based on body weight. Your healthcare provider will adjust the dose based on changes in weight following regular check-ups.
- Your healthcare provider will monitor the patient's growth and tell you when to stop taking VOXZOGO if they determine the patient is no longer able to grow. Stop administering VOXZOGO if instructed by your healthcare provider.

What should you tell the doctor before or during taking VOXZOGO?

- Tell your doctor about all of the patient's medical conditions including
 - If the patient has heart disease (cardiac or vascular disease), or if the patient is on blood pressure medicine (anti-hypertensive medicine).
 - If the patient has kidney problems or renal impairment.
 - If the patient is pregnant or plans to become pregnant. It is not known if VOXZOGO will harm the unborn baby.
 - If the patient is breastfeeding or plans to breastfeed. It is not known if VOXZOGO passes into breast milk.
- Tell your doctor about all of the medicines the patient takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

You may report side effects to BioMarin at **1-866-906-6100**. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call **1-800-FDA-1088**.

Please see additional safety information in the full [Prescribing Information](#) and [Patient Information](#).

VOXZOGO®
(vosoritide) for injection

Are you ready to take the next step?



Visit VOXZOGO.com to:



Connect with us—get updates, resources, and answers to your questions about VOXZOGO® (vosoritide)



Find a healthcare provider in your area



Find events near you

it's **GO** time

Annika, 14 years old,
receiving VOXZOGO as
part of a clinical trial



What is the most important safety information about VOXZOGO?

- VOXZOGO may cause serious side effects including a temporary decrease in blood pressure in some patients. To reduce the risk of a decrease in blood pressure and associated symptoms (dizziness, feeling tired, or nausea), patients should eat a meal and drink 8 to 10 ounces of fluid within 1 hour before receiving VOXZOGO.

Please see **Important Safety Information** throughout, as well as the full **Prescribing Information** and **Patient Information**.

VOXZOGO®
(vosoritide) for injection

BIMARIN®